Focus: Thea Pharma is a publicly traded ophthalmic pharmaceutical company headquartered in Waltham, MA, focused on glaucoma, dry eye, and corneal diseases. The company operates a portfolio of established and emerging eye care therapies with concentrated revenue from legacy products.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Thea Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product generating 50% of company revenue but vulnerable to generic competition as the flagship beta-blocker in a commoditized glaucoma market.
Help build intelligence for Thea Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Thea Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor (prostaglandin agonist) entering exclusivity cliff in 2029; peak performance masks medium-term erosion risk.
Combination therapy with sustained market presence; preservative-free formulation provides minor differentiation in maturing glaucoma market.
Late-life cycle product with extended LOE window (2031) but modest revenue contribution reflecting commodity pricing in prostaglandin class.
Newest commercial launch with dual indication (glaucoma + cosmetic hypotrichosis) and extended patent window (2036) offering growth potential and market differentiation.
2 discontinued, 2 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moTwo lidocaine injection shortages (marked 'Available') suggest supply chain monitoring but no acute safety or compliance crises; however, zero transparency on organizational changes warrants caution.